Myriad Genetics Stock Craters on Weak Earnings, FDA Scrutiny - Barron's

Submitted by Anonymous (not verified) on Wed, 08/14/2019 - 12:55

Myriad Genetics Stock Craters on Weak Earnings, FDA Scrutiny  Barron'sShares of the molecular-diagnostic biotech firm Myriad Genetics crashed in premarket trading on Wednesday, down 30.4% as of 8:30 a.m., after the company ...